The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement (OTA) to AstraZeneca Pharmaceuticals LP, a foreign-owned for-profit pharmaceutical manufacturer, on October 28, 2020. The award has a potential value of $857,061,969.19 and is focused on the development of AstraZeneca's COVID-19 vaccine.
AstraZeneca has a history of providing a range of pharmaceutical products and medical countermeasures to federal agencies, including influenza vaccines, COVID-19 treatments, monoclonal antibodies, and other pharmaceuticals to the Department of Health and Human Services, Department of Defense, and Department of Veterans Affairs. The company also holds several federal Indefinite Delivery Vehicles (IDVs) for pharmaceutical products with agencies such as the Centers for Disease Control and Prevention and the Department of Veterans Affairs, which have been used to procure influenza vaccines and other medical countermeasures.
Generated 3/27/24, 9:09 AM